mTORC2-mediated PDHE1α nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to cancer metastasis in nasopharyngeal carcinoma

Jun Zhang1 · Lin Jia1 · Tengfei Liu1 · Yim Ling Yip1 · Wing Chung Tang1 · Weitao Lin1 · Wen Deng1,2 · Kwok Wai Lo3 · Chanping You1 · Maria Li Lung4,5 · Hong Lok Lung6 · Annie Lai-Man Cheung1 · Sai Wah Tsao1,5 · Chi Man Tsang1

Received: 26 November 2018 / Revised: 24 January 2019 / Accepted: 26 January 2019 / Published online: 11 February 2019
© The Author(s) 2019. This article is published with open access

Abstract
EBV infection of preinvasive nasopharyngeal epithelium is believed to be an initiation step during pathogenesis of nasopharyngeal carcinoma (NPC), but the mechanisms remain poorly understood. Here we report a novel mechanism driving NPC metastasis through the EBV-encoded LMP1-mediated metabolic reprogramming, via activation of IGF1-mTORC2 signaling and nuclear acetylation of the Snail promoter by the PDHE1α, an enzyme involved in glucose metabolism. Mechanistically, EBV-LMP1 increases the cellular secretion of IGF1 which promotes phosphorylation of IGF1R to activate mTORC2/AKT signaling linking glucose metabolism to cell motility. LMP1 expression facilitates translocation of mitochondrial PDHE1α into the nucleus in a phosphorylation-dependent manner at Ser293 residue. Functionally, nuclear PDHE1α promotes H3K9 acetylation on the Snail promoter to enhance cell motility, thereby driving cancer metastasis. Importantly, the IGF1/mTORC2/PDHE1α/Snail axis correlates significantly with disease progression and poor prognosis in NPC patients. This study highlights the functional importance of IGF1-mTORC2-PDHE1α signaling mediated by EBV-LMP1 in NPC pathogenesis.

Introduction
Oncogenic viruses commonly interfere with the host metabolic signaling pathways to exert their transformation properties [1]. Epstein-Barr virus (EBV) is a human γ-herpesvirus closely associated with both lymphoid [2] and epithelial malignancies including nasopharyngeal carcinoma (NPC) [3, 4] and gastric cancer [5]. EBV-associated NPC is a special type of head and neck cancer, which is highly invasive and metastatic [6]. EBV infection in NPC is predominantly latent in nature with restricted expression of viral proteins notably the latent membrane protein-1 (LMP1) [3, 4]. LMP1 is a well-characterized oncogene encoded by EBV and has been postulated to play an essential role in NPC pathogenesis [7, 8]. The roles of LMP1 in glycolysis addiction, a common hallmark of cancer, is emerging as an important mediator in NPC pathogenesis and progression [9–13]. The role of EBV-LMP1 in modulating metabolic pathways to promote dissemination of tumor cells has not been previously reported.

Tumor metastasis is a major cause of treatment failure [14]. Epithelial-mesenchymal transition (EMT) is an essential process in tumor metastasis. The involvement of
**Results**

**EBV infection induces glycolytic addiction in nasopharyngeal epithelial cells**

Infection of EBV in three hTERT-immortalized nasopharyngeal epithelial (NPE) cells was confirmed by expression of green fluorescent protein tagged to EBV genome and detection of EBV-DNA fluorescence in situ hybridization (Fig. S1A). Expression of latent EBV genes (EBER, EBNA1, LMP1, and LMP2A) in infected NPE cells was detected by western blotting and reverse transcription-PCR (Fig. S1B–C). The differentially expressed genes (DEG) of EBV-infected and -uninfected cells were shown in the Venn diagrams after normalization revealing 249 downregulated genes and 302 upregulated genes (Fig. 1a). A heatmap representing these two groups of DEGs was generated (Fig. 1a; specific gene names and functions are shown in Table S1). We further performed the enrichment analysis of these DEGs based on the Gene Ontology Consortium (GO) database [24] and observed a large population of genes are involved in cell metabolism (Fig. 1b). Using gene set enrichment analysis (GSEA) [15], we observed that genes involved in glycolysis and pyruvate metabolism were statistically enriched in EBV-infected cells supporting a role of EBV infection in metabolic reprogramming (Fig. 1c; Fig. S2A–B). A heatmap generated with the key enzymes involved in glycolysis and pyruvate metabolic process also indicated their upregulation in EBV-infected cells (Fig. 1d). Uptregulation of glycolysis enzymes and downregulation of oxidative phosphorylation enzymes in EBV-infected cells were confirmed using western blot (Fig. 1e) and RT-PCR (Fig. S2C). We also detected an enhanced glycolysis phenotype in EBV-infected cells by comparing their extracellular acidification ratio (ECAR) and oxygen consumption ratio (OCR) (Fig. 1f; Fig. S2E). Furthermore, EBV-infected cells were more sensitive to 2-deoxy-D-glucose (2-DG; a glucose analog used as a glycolytic inhibitor) while EBV-uninfected cells were more sensitive to oligomycin (a mitochondrial ATP synthesis inhibitor) (Fig. S2D) providing further evidence that EBV-infected cells were addictive to glycolysis. These results support a reprogramming of glucose metabolism in EBV-infected NPE cells from oxidative phosphorylation (OXPHOS) to aerobic glycolysis.

**EBV-LMP1 is involved in reprogramming the glucose metabolism**

We further confirmed the involvement of LMP1 in conferring the altered metabolic phenotype by suppressing LMP1 expression by shLMP1 (Fig. S2F). Suppression of LMP1 resulted in downregulation of key glycolytic genes (Fig. S2G) and proteins (Fig. 1g). We also observed a higher lactate production and lower oxygen consumption in control cells compared with the shLMP1-transfected cells (Fig. 1h and Fig. S2I). Furthermore, suppression of LMP1 also reduced sensitivity to 2-DG and enhanced sensitivity to oligomycin (Fig. S2H).

Both western blot (Fig. 1i) and RT-PCR (Fig. S2J) also confirmed that LMP1 enhanced the expression of glycolytic enzymes but reduced the OXPHO enzymes. An enhanced glycolytic phenotype was also observed in LMP1-expressing NPE cell lines, which produced more lactate but consumed less oxygen compared to control cells (Fig. 1j). Furthermore, LMP1-expressing cells were more sensitive to 2-DG but less sensitive to oligomycin.
confirming that LMP1-expressing cells were more dependent on glycolysis (Fig. S2K). All these findings support the involvement of LMP1 in mediating EBV-driven metabolic reprogramming.

**Glycolysis is involved in LMP1-enhanced cell motility in NPE cells**

LMP1 has been reported to induce EMT and metastatic properties in NPC [25, 26]. Our study confirmed that LMP1 expression induces EMT in NPE cells (Fig. 2a). To investigate the involvement of glycolysis in cell motility, we treated LMP1-expressing cells with glycolytic inhibitors, 2-DG and STF-31 (a selective inhibitor for the glucose transporter-1). These chemicals effectively attenuated LMP1-enhanced EMT in a dose-dependent manner (Fig. 2a), suppressed migration and invasion (Fig. 2b), and wound healing (Fig. 2c and Fig. S3A). Live-cell tracking over 24 h period also revealed suppression of LMP1-enhanced cell migration in the presence of glycolytic inhibitors (Fig. 2d and Movie S1–4). We then separated the LMP1-overexpressing NP69 cells into high- and low-invasive populations by plating them in an invasion chamber coated with Matrigel. High-invasive cell
population (which migrated through the invasion chamber) and low-invasive cell population (which remained in the upper chamber) were obtained (Fig. 2e). Western blot analysis revealed higher expression of glycolytic enzymes in the high-invasive cell populations compared to the low-invasive cell populations (Fig. 2f). A higher rate of glucose uptake and lactate production was also observed in the high-invasive cell population implicating the involvement of
glycolysis in mediating LMP1-enhanced cell motility (Fig. 2g).

**LMP1 activation of mTORC2 by autocrine secretion of IGF1 links EBV-reprogrammed glucose metabolism to cell motility**

Our RNA-sequencing data showed enrichment of genes in PI3K/AKT as well as mTOR signaling in EBV-infected NPE cells (Fig. 3a; Fig. S4A–B). We have previously reported that LMP1 activates mTORC1 to enhance glycolysis [9]. Here we report that mTORC2 was activated in EBV-infected NPE cells (Fig. 3b). Knockdown of Rictor not only abrogated phosphorylation of AKT at Ser473 and downregulated multiple glycolytic enzymes (Fig. 3c) but also lowered the rates of glycolysis (Fig. 3d, e). Suppression of glycolysis was observed after blocking AKT activation (Fig. S5A–C). All these supported a role of mTORC2, in mediating LMP1-induced glycolysis.

We further demonstrated that inhibition of mTORC2/AKT signaling could reverse LMP1-induced EMT, as indicated by the downregulation of mesenchymal markers but upregulation of epithelial markers (Fig. 3f and Fig. S5B). Suppression of mTORC2/AKT signaling also attenuated LMP1-induced cell motility (Fig. 3g and Movie S5–9) and invasive properties (Fig. S4C–E, and S5D–G). Our supplementary results using gene knockdown and inhibitor approaches supported a more prominent role of mTORC2 in LMP1-enhanced cell motility (Fig. S4C).

We further investigated the involvement of autocrine mechanisms in mTORC2 signaling activation by LMP1 (Fig. S6A). Both cell proliferation and mTORC2 activation in parental cells were enhanced after incubating with conditioned medium harvested from LMP1-expressing cells (Fig. 3h, i). Previous study had reported that LMP1 promotes IGF1 expression to drive cell proliferation [27], which was confirmed in immortalized NPE cell (Fig. S6B). Increased expression of IGF1 was associated with activation of mTORC2 in LMP1-expressing NP69 cells (Fig. 3j). Treatment with neutralizing antibody against IGF1 or IGF1R inhibitor AG-1024 suppressed LMP1-induced mTORC2 activation (Fig. 3k) and its downstream events including cell proliferation (Fig. S6C), glucose metabolism (Fig. S6D&E), and cell motility (Fig. S6F&G). These results support an important role of LMP1/IGF1/IGF1R signaling axis to activate mTORC2 and its downstream events.

**Nuclear localization of PDHE1α is involved in mediating LMP1-enhanced motility**

Pyrurate can be converted to acetyl-CoA in OXPHOS by the pyruvate dehydrogenase (PDH) complex in normal cells. Notably, our heatmap summarizing the changed expression of glycolysis enzymes including PDHA1 (also known as PDHE1α) (Fig. 1d). We have investigated the role of PDHE1α in LMP1-mediated cell motility. Knocking down PDHE1α suppressed the LMP1-enhanced EMT (Fig. 4a). Interestingly, immunofluorescence staining revealed an increase of PDHE1α in nucleus but a decrease in mitochondrion suggesting a nuclear translocation of PDHE1α from mitochondria to nucleus in LMP1-expressing cells (Fig. 4b). We further confirmed the nuclear translocation of PDHE1α by western blot analysis of cytosolic (C), nuclear (N), and mitochondrial (M) subcellular fractions (Fig. 4c). In addition, knockdown of Rictor suppressed nuclear levels of PDHE1α (Fig. S7A), which implicates that LMP1 activation of mTORC2 is involved in regulating the nuclear accumulation of PDHE1α. Phosphorylation of PDHE1α at Ser293 by its upstream kinase, PDHK1, is a common event in cancer cells [28]. We further showed that blocking the PDHK1 activation by expression of its dominant negative mutant (PDHK1-T346A) suppressed the LMP1-mediated nuclear accumulation of PDHE1α (Fig. S7B). The role of phosphorylation of Ser293 of PDHE1α in its nuclear accumulation was shown by the following experiments. The endogenous PDHE1α was first knocked down by short
hairpin RNA (referred as NP69-PDHE1α-KD cells), then followed by either overexpression of the wild-type (WT) construct of PDHE1α (PDHE1α-WT) or the constitutive activation of phosphomimic PDHE1α construct (PDHE1α-S293D). Reconstitutive expression of the WT or S293D-PDHE1α constructs, but not with the phosphorylation-dead PDHE1α construct (PDHE1α-S293A), significantly enhanced nuclear localization of PDHE1α (Fig. 4d). Moreover, the EMT markers, accumulated cell motility distance as well as migration and invasion properties were also restored after reconstitutive expression of PDHE1α or S293D-PDHE1α (Fig. 4e–g). Taken together, these results support that Ser293 phosphorylation of PDHE1α is responsible for its nuclear localization to mediate the LMP1-enhanced cell motility.

**Nuclear PDHE1α promotes histone acetylation of Snail promoter to mediate LMP1-enhanced cell motility**

Nuclear PDHE1α has recently been reported to promote histone acetylation to control cell cycle progression [22, 23]. Interestingly, expression of LMP1 as well as EBV infection also elevated the H3K9 acetylation (Fig. 5a).
mTORC2-mediated PDHE1α nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to...
Fig. 4 Nuclear translocation of PDHE1α is involved in mediating LMP1-enhanced EMT and motility in NPE cells. a NP69 cells with overexpression of LMP1 were infected with shPDHE1α or control vector for 48 h, cells were lysed, and subjected to western blotting for detecting the expression of cell motility-associated proteins. b Cells were co-stained with MitoTracker Red (mitochondrial marker), PDHE1α (green), and Hoechst33258, and representative images were taken using a Zeiss LSM800 system. The nuclear signaling intensity was analyzed and is shown in histogram. c Subcellular fractionations of NP69 and NP69-LMP1 were isolated for demonstrating the localization of indicated proteins in various subcellular compartments. GAPDH, COX IV, and Histone H3 were used as cytosol, mitochondrial, and nucleus markers respectively. d NP69-PDHE1α-KD cells were first stably reconstituted with either wild-type (WT) or mutant PDHE1α, and then transfected with pcDNA or pcDNA-LMP1, followed by co-staining with MitoTracker Red (mitochondrial marker), PDHE1α (green), and Hoechst33258. Representative images were taken using a Zeiss LSM800 system. e Indicated cells were also analyzed by western blotting for detecting the expression of cell motility-associated markers. f Cells were seeded on the coverglass chamber and observed under time-lapse microscope. Representative tracks of cell movements that were traced and visualized using metaphase software every 10 min for 24 h. The accumulated distance was analyzed by metaphase software. g Cell migration and invasion were assayed using uncoated Millipore Transwell chambers and coated ones with Matrigel respectively. Representative images of cells at the bottom surface are shown. The number of cells in five random fields were counted for each group. Data are means ± SD (means ± SEM for b, d, f). *p < 0.05; **p < 0.01; ***p < 0.005
Involvement of IGF1/mTORC2/PDHE1α/Snail axis is associated with NPC progression and poor prognosis in clinical specimens of NPC

A cohort of 101 cases of NPC and 9 cases of NPC adjacent normal tissues was examined by immunocytochemistry. The clinico-pathologic variables are summarized in Table 1. The expression of IGF1/mTORC2/PDHE1α/Snail signaling members was determined by immunocytochemistry. Representative immunostainings are shown in Fig. 7a. Significantly increased expression of IGF1, pAKT, pPDHE1α, and Snail was observed in advanced NPC stages (stage II, III, and IV) and their lymph node metastasis, but low or absent in normal nasopharyngeal tissues and stage 1 NPC (Fig. 7b). High expression of pPDHE1α and Snail was significantly associated with advanced N staging (p = 0.0389 and 0.0122) and clinical stages (p < 0.001 and p = 0.0286). The H-scoring cohort showed a positive association of high expression of pPDHE1αSer293 in NPC tissue with IGF1 (p = 0.0004, $r^2 = 0.5488$), pAKTser473 (p < 0.0001; $r^2 = 0.6015$), and Snail (p = 0.0001, $r^2 = 0.3493$) (Fig. 7c, d). LMP1 expression also positively correlated with IGF1/AKT. Association of LMP1 expression with pPDHE1α/Snail was not significant (Fig. S9). A lower
Overall survival rates were observed in patients with high expression of pPDHE1αSer293 (p = 0.0199, hazard ratio (HR) = 0.476) and Snail (p = 0.0238, HR = 0.478) (Fig. 7e). Similarly, the group with high expression of both pPDHE1αSer293 and Snail had a significantly lower survival rate (Fig. 7e). Taken together, our data supports the clinical relevance of IGF1/mTORC2/PDHE1 axis in NPC and their clinical application in disease progression and patient prognosis.

Discussion

Despite the close association of NPC with EBV, the role of EBV infection in NPC pathogenesis remains poorly defined [3]. In this study, using various EBV-infected NPE cell systems and bona fide EBV-positive NPCs, we have demonstrated a pathological role of EBV and its encoded oncogene, LMP1, in driving cell motility through metabolic reprogramming. A detailed schematic diagram summarizing our findings is shown in Fig. 5f.

EBV infection is believed to be an early and essential event during NPC pathogenesis [31]. Alteration of molecular pathways in EBV-infected premalignant NPE cells, which facilitates their malignant transformation has been suggested [3, 4]. The switch to aerobic glycolysis is believed to be beneficial to support cell proliferation in cancer by providing essential intermediates [32]. A recent study has reported that growth arrest of EBV-infected B cells could be induced in the presence of shortage of metabolite supply [33]. A role of LMP1 to support aerobic glycolysis has been reported in multiple studies [9, 10, 12, 34]. LMP1-enhanced glycolysis has been shown to enhance malignant properties of NPC cells [9, 10] by development of chemotherapy resistance [12] and immune escape [13]. In this study, we report a novel role of LMP1-induced glycolysis in promoting cell motility through the mTORC2 signaling. The activation of mTORC2 by LMP1 has been mentioned in a recent study, but the underlying mechanism remains to be defined [35]. In this study, we showed that LMP1 activates mTORC2 through an autocrine activation of IGF1R signaling. Blocking the IGF1-IGF1R signaling axis by neutralizing antibody or IGF1R inhibitor suppressed the activation of mTORC2/AKT signaling. Our observations are consistent with the general concept that mTORC2 activation is responsive to growth factors [36]. Elucidation of the underlying signaling axis may contribute to identification of novel therapeutic targets to control NPC progression.

The involvement of metabolic reprogramming in enhancement of cancer cell motility has been implicated [37]. Several core metabolic enzymes, including PGAM and PKM2, have been shown to have physiological functions in cell motility [19, 38]. Our study showed that PDHE1α, which functions as the primary link between glycolysis and TCA cycle, is closely associated with LMP1-induced cell motility. Previous study has reported that translocation of PDHE1α to nucleus promotes acetylation of histones to modulate multiple cellular activities [23]. In this study, we showed that knockdown of PDHE1α or expression of PDHE1α Ser293 mutant significantly attenuated LMP1-induced cell motility. We also demonstrated that Ser293 phosphorylation of PDHE1α is essential for its nuclear translocation linking LMP1-induced glucose metabolism to cell motility. The mTORC2/AKT signaling has been reported to mediate glycolysis by regulating the phosphorylation and activation of the glycolytic enzyme, PDHK1, in mitochondria [21]. Our study showed that suppression of mTORC2 or inactivation of PDHK1 decreased the nuclear translocation of PDHE1α. All these observations suggest that LMP1-mediated mTORC2/AKT signaling can mediate PDHE1α phosphorylation and nuclear translocation to modulate gene expression, which are novel properties of LMP1.

The involvement of nuclear PDHE1α to activate Snail promoter through epigenetic modification to enhance cell motility is another novel finding. Detailed mechanism that regulating the trafficking of PDHE1α remains to be defined. It was reported that Hsp70 could promote nuclear translocation of the PDH complex by competing with PDHK1 for binding to PDHE1 in a growth factor-dependent manner [23, 39]. In this study, we showed that the LMP1 induces secretion of IGF1 to activate mTORC2/AKT to promote phosphorylation and translocation of PDHE1α into the nucleus to induce acetylation of histone H3 at lysine residue 9. By luciferase assay and ChIP assay, H3K9Ac was shown to be recruited to the promoter region of Snail, a well-characterized regulator of EMT [40]. Our in vitro and in vivo models also support a role of PDHE1α in facilitating NPC invasion and metastasis [28]. The detailed involvement of PDHE1α remains to be further delineated.

In summary, the current study reveals a novel role of EBV infection in promoting migratory and invasive ability
of NPC cells involving perturbed glucose metabolic pathways and nuclear translocation of PDHE1α mediated by LMP1/IGF1/mTORC2 signaling axis and may reveal new and potentially effective therapeutic target in clinical management of NPC.

**Materials and methods**

**Cell lines and cell culture**

The NP361hTert, NP460hTert, and NP550hTert are telomerase-immortalized nonmalignant human NPE cell lines established by our laboratory [41–43]. They were cultured in a 1:1 ratio of growth factor supplemented DKSFM and EpiLifeTM medium (GIBCO, Life TechnologiesTM, Grand Island, NY). The immortalized NP69 NPE cell line with high transfection efficiency and low signaling background [44] was cultured in KSF medium (GIBCO). The 293 cells were cultured in Dulbecco’s modified Eagle’s medium (Sigma) supplemented with 10% (vol/vol) fetal bovine serum (FBS; GIBCO), 100 U/ml of penicillin, and 100 U/ml of streptomycin. C666-1 cells were cultured in RPMI medium with 10% (vol/vol) FBS, and NPC43 cells were cultured in RPMI medium with 10% (vol/vol) FBS and 4 μM Rock inhibitor. The NPE cells were infected with EBV using a previously published protocol [45].

**Chemicals and reagents**

The glucose metabolism-associated inhibitor STF-31 (S7931), AKT signaling inhibitor MK2206 (S1078), and IGF1R tyrosine inhibitor AG-1024 (S1234) were purchased from Selleckchem (Houston, TX); and ROCK inhibitor (ALX-270-333-M025) was got from Enzo Life Sciences (USA). LY294002 (440204) and Oligomycin (495455) were purchased from Calbiochem (Germany). 2-DG (D8375) was purchased from Sigma (St. Louis, Missouri, USA). Fluorescein isothiocyanate-gelatin was obtained from Life Technologies (G13187).

### Table 1: Correlation between expressions of pPDHE1αSer293 and Snail and clinicopathological features of human NPC

| Characteristic | All cases | pPDHE1αSer293 protein level | Snail protein level |
|---------------|-----------|-----------------------------|-------------------|
|               |           | Low | High | χ² | p Value | Low | High | χ² | p Value |
| Age (years)   |           |     |      | χ² | p Value |     |      | χ² | p Value |
| ≤50           |           | 28  | 13 (46.43%) | 15 (53.37%) | 0.0171 | 0.8959 | 12 (42.86%) | 16 (57.14%) | 1.5936 | 0.2068 |
| >50           |           | 71  | 34 (47.89%) | 37 (52.11%) | 0.2719 | 0.6021 | 21 (29.58%) | 50 (70.42%) | 2.0842 | 0.1488 |
| Sex           |           |     |      | χ² | p Value |     |      | χ² | p Value |
| Female        |           | 19  | 8 (42.11%) | 11 (57.89%) | 0.1943 | 0.6608 | 9 (43.75%) | 10 (56.25%) | 0.2703 | 0.1012 |
| Male          |           | 80  | 39 (48.75%) | 41 (51.25%) | 0.0436 | 0.8365 | 24 (30.00%) | 56 (70.00%) | 0.0002 | 0.9552 |
| TNM stages    |           |     |      | χ² | p Value |     |      | χ² | p Value |
| T stage       |           |     |      | χ² | p Value |     |      | χ² | p Value |
| T1            |           | 23  | 10 (43.48%) | 13 (56.52%) | 5.3532 | 0.1477 | 13 (56.52%) | 10 (43.48%) | 14.3672 | 0.0024 |
| T2            |           | 27  | 17 (62.96%) | 10 (37.04%) | 0.5804 | 0.4458 | 12 (44.44%) | 15 (55.56%) | 0.0002 | 0.9552 |
| T3            |           | 19  | 10 (52.63%) | 9 (47.37%) | 0.1943 | 0.6608 | 5 (26.32%) | 12 (63.68%) | 0.2703 | 0.1012 |
| T4            |           | 30  | 10 (33.33%) | 20 (66.67%) | 8.3745 | 0.0389 | 3 (10.00%) | 27 (90.00%) | 10.9117 | 0.0122 |
| N stage       |           |     |      | χ² | p Value |     |      | χ² | p Value |
| N0            |           | 20  | 13 (65.00%) | 7 (35.00%) | 0.1943 | 0.6608 | 11 (55.00%) | 9 (45.00%) | 0.0002 | 0.9552 |
| N1            |           | 33  | 19 (57.58%) | 14 (42.42%) | 14.3672 | 0.0024 | 14 (42.42%) | 19 (57.58%) | 0.0002 | 0.9552 |
| N2            |           | 37  | 13 (35.14%) | 24 (64.86%) | 0.0024 | 0.9552 | 7 (18.92%) | 30 (81.08%) | 0.0002 | 0.9552 |
| N3            |           | 9   | 2 (22.22%) | 7 (77.78%) | 8.3745 | 0.0389 | 1 (11.11%) | 8 (88.89%) | 0.0002 | 0.9552 |
| M stage       |           |     |      | χ² | p Value |     |      | χ² | p Value |
| M0            |           | 93  | 46 (49.46%) | 47 (50.54%) | 2.4311 | 0.1190 | 22 (23.66%) | 71 (76.34%) | 0.0154 | 0.6944 |
| M1            |           | 6   | 1 (16.67%) | 5 (83.33%) | 21.7219 | <0.0001 | 1 (16.67%) | 5 (83.33%) | 9.0560 | 0.0286 |

NPC nasopharyngeal carcinoma

*Chi-square test; values in bold-italic were defined as statistical with significant differences (p < 0.05)*
mTORC2-mediated PDHE1α nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to...
Bioinformatic analysis of the RNA-sequencing data

The libraries were prepared using the Illumina TruSeq mRNA Library Prep Kit according to the manufacturer’s instructions. Sequencing was performed on an Illumina HiSeq2000 sequencing system (Illumina, San Diego, CA, USA). The gene expression ratio between EBV-infected cells and parental cells was calculated based on the fragments per kilobase million value of each gene. The thresholds for DEGs were set as fold-change > 1.4 or fold-change < 0.7. The up- and downregulated genes in each group respectively were subjected to Venn diagram to illustrate the overlapping genes among the three pairs of cell lines used. The overlapping genes were then subjected to GO for enrichment analysis [24]. GSEA was used to characterize the differences in transcriptome profiles of EBV-positive cells compared to the EBV-negative cells in specific signatures [15]. This method considers the full list of genes, ranked by their correlation with phenotype, and calculates an enrichment score to determine whether the analyzed genes were enriched at specific signatures.

Assays of extracellular acidification and oxygen consumption

The micro-plate reader system (Victor, PerkinElmer) was used to measure OCR and ECAR. Cells were plated in a 96-well plate with a density of 10,000 cells/well and incubated in a 37 °C incubator for 24 h. After the indicated treatment, cells were incubated with ECAR or OCR reagents according to the manufacturer’s recommendations (ab197244 for ECAR and ab197243 for OCR, Abcam, UK). The ECAR and OCR assay signals were collected at 5 min intervals for about 120 min using excitation and emission wavelengths of 380 and 615 nm respectively.

Cell motility tracking

Cells were seeded in Lab-Tek glass-bottomed eight-chambered slide (155411, Thermo Scientific) and pre-treated as indicated. The chambered slide was then placed on the contained stage of microscope with 5% CO₂ at 37 °C. Cell motility was monitored with the widefield microscope (Zeiss, Germany). Cell positions were recorded at every 10-min interval over a period of 24 h and then processed with Track Object Tool in Metamorph analysis software.

Subcellular fractionation

The subcellular fractions were isolated following a previous published protocol [46].

ChIP assay

ChIP was performed using a ChIP assay kit (520127, Covaris) following a previously described protocol [9]. Briefly, cells were crosslinked and then lysed. Sheared DNA was incubated overnight at 4 °C with primary antibodies against H3K9Ac (#9649, CST) or normal rabbit IgG (sc-2027, Santa Cruz), followed by adding 50 µl magnetic bead into the mixture and incubating at 4 °C for 2 h. The chromatin was then washed, the crosslinking was reversed, and the DNA was purified using a Monarch® PCR & DNA Cleanup Kit (T1030S, NEB). The purified DNA products were subjected to PCR analysis using SYBR Green system (B21203, Biotool). Primers are listed in Table S3.

Tissue microarray

The human NPC tissue microarray containing 110 samples of different clinical stages was obtained from Queen Mary Hospital, HKU. The staining was scored using a semi-quantitative scoring system incorporating the proportion of the intensity of staining (0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining). The expression levels of the proteins were evaluated by multiplying the score of percentage of positive cell with the score of staining intensity and was evaluated in a blinded fashion (H-score = 1 × percentage of weak staining cell + 2 × percentage of moderate staining cell + 3 × percentage of strong staining cell). The protocol of immunohistochemical staining was performed as described previously [10, 42]. The use of clinical samples was approved by the Research Ethics Committee of HKU.

Experimental in vivo metastasis study

Male nude or NOD/SCID mice at 6 weeks of age were housed in a specific pathogen-free room with the Guide for
the Care and Use of Laboratory Animals of the University of Hong Kong. The mice were randomly divided into different groups before the injection. Luciferase-expressing C666-1 cells with different engineering constructs were resuspended in 100 μl PBS (1 x 10^6 cells), and were then injected into the tail veins of mice. The mice were observed under the PE IVIS Spectrum in vivo imaging system (PerkinElmer) 6 weeks after injection. Ten weeks later, the mice were sacrificed, and the lungs were removed and fixed for hematoxylin and eosin staining.

Statistical analysis

Data are expressed as means ± SD or SEM from three independent triplicates and were analyzed with GraphPad Prism 5 statistical software. The χ²-test was used to analyze the correlation between pPDHE1α-Ser293 and Snail expression and clinicopathological features. The overall survival probability of NPC patients was calculated using the Kaplan-Meier method and differences were compared using the log-rank test. The differences between experimental groups were analyzed with the Dennett t-test; p values of 0.05 were considered statistically significant.

The details for western blot, RT-PCR, lentiviral package, luciferase report assay, wound healing, and migration/invasion assays are described in the Supplementary information.

Data availability

RNA sequencing raw data have been deposited at SRA with reference number as PRJNA515597.

Acknowledgements

We acknowledge the Faculty Core Facility members of HKU and Mr. Tony Chan for technical supports. SWT and KWL are funded by the Research Grants Council, Area of Excellence NPC (Grant No. AoE/M 06/08), Theme-Based Research Scheme (T12-401/13-R), Collaborative Research Fund (C7027-16G, C4001-18GF and C1013-15G), General Research Fund (14117316, 17116116, 17120814, 779713, and 779312), and Health and Medical Research Fund (04151726). CMT is funded by the Health and Medical Research Fund (05162386 and 13142201) and General Research Fund (17110315 and 17111516).

Author contributions

JZ and SWT conceived this project. JZ performed experiments and wrote the manuscript. JZ, LJ, and CMT analyzed the data. SWT and CMT secured funding and revised the manuscript. LJ and KWL are funded by the Research Grants Council, Area of Excellence NPC (Grant No. AoE/M 06/08), Theme-Based Research Scheme (T12-401/13-R), Collaborative Research Fund (C7027-16G, C4001-18GF and C1013-15G), General Research Fund (14117316, 17116116, 17120814, 779713, and 779312), and Health and Medical Research Fund (04151726). CMT is funded by the Health and Medical Research Fund (05162386 and 13142201) and General Research Fund (17110315 and 17111516).

Conflict of interest

The authors declare that they have no conflict of interest.

References

1. Levy P, Bartosch B. Metabolic reprogramming: a hallmark of viral oncogenesis. Oncogene. 2016;35:4155–64.
2. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1964;1:702–3.
3. Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. 2017;372:20160270.
4. Tsao SW, Tsang CM, To KF, Lo KW. The role of Epstein-Barr virus in epithelial malignancies. J Pathol. 2015;235:323–33.
5. Niedobitek G, Herbst H, Young LS, Rowe M, Dienemann D, Germer C, et al. Epstein-Barr virus and carcinomas. Expression of the viral genome in an undifferentiated gastric carcinoma. Diagn Mol Pathol. 1992;1:103–8.
6. Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016;387:1012–24.
7. Tsao SW, Tramoutanis G, Dawson CW, Lo AK, Huang DP. The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12:473–87.
8. Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-kappaB pathway activating mutations. Nat Commun. 2017;8:14121.
9. Zhang J, Jia L, Lin W, YipYL, Lau YM, et al. Epstein-Barr virus-encoded latent membrane protein 1 upregulates glucose transporter 1 transcription via the mTORC1/NF-kappaB signaling pathways. J Virol. 2017;91:e02168–16.
10. Lo AK, Dawson CW, Young LS, Ko CW, Hau PM, Lo KW. Activation of the FGFR1 signalling pathway by the Epstein-Barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells. J Pathol. 2015;237:238–48.
11. Zhang J, Jia L, Tsang CM, Tsao SW. EBV infection and glucose metabolism in nasopharyngeal carcinoma. Adv Exp Med Biol. 2017;1018:75–90.
12. Xiao L, Hu ZY, Dong X, Tan Z, Li W, Tang M, et al. Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy. Oncogene. 2014;33:4568–78.
13. Cai TT, Ye SB, Liu YN, He J, Chen QY, Mai HQ, et al. LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma. PLoS Pathog. 2017;13:e1006503.
14. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127:679–95.
15. Ren X, Yang X, Cheng B, Chen X, Zhang T, He Q, et al. HOXD hypermethylation promotes metastasis via activating SNAIL
transcription in nasopharyngeal carcinoma. Nat Commun. 2017;8:14053.

16. Hecht I, Natan S, Zaritsky A, Levine H, Tarasfati I, Ben-Jacob E. The motility-proliferation-metabolism interplay during metastatic invasion. Sci Rep. 2015;5:13538.

17. Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211–8.

18. Hamabe A, Konno M, Tanuma N, Shima H, Tsunekuni K, Kawamoto K, et al. Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition. Proc Natl Acad Sci USA. 2014;111:15526–31.

19. Zhang D, Jin N, Sun W, Li X, Liu B, Xie Z, et al. Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity. Oncogene. 2017;36:2900–9.

20. Wang XM, Proud CG. mTORC2 is a tyrosine kinase. Cell Res. 2016;26:1–2.

21. Chae YC, Vaira V, Ciano MC, Tang HY, Seo JH, Kossenkov AV, et al. Mitochondrial Akt regulation of hypoxic tumor reprogramming. Cancer Cell. 2016;30:257–72.

22. Nagaraj R, Sharples MS, Chi F, Braas D, Zhou Y, Kim R, et al. Nuclear localization of mitochondrial TCA cycle enzymes as a critical step in mammalian zygotic genome activation. Cell. 2017;168:210–23.e11.

23. Sutendra G, Kinnaird A, Dromparis P, Paulin R, Stenson TH, et al. Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma. Nat Commun. 2018;9:4663.

24. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene Ontology: tool for the unification of biology. Nat Genet. 2000;25:25–9.

25. Horikawa T, Yoshizaki T, Kondo S, Furukawa M, Kaizaki Y, Pagano J. Epstein-Barr Virus latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma. J Pathol. 2018;246:180–90.

26. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–76.

27. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.

28. Wang XM, Proud CG. mTORC2 is a tyrosine kinase. Cell Res. 2016;26:1–2.

29. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med. 1995;333:693–8.

30. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

31. McFadden K, Hafez AY, Kishton R, Messinger JE, Nikitin PA, Rathnec JC, et al. Metabolic stress is a barrier to Epstein-Barr virus-mediated B-cell immortalization. Proc Natl Acad Sci USA. 2016;113:E782–90.

32. Sommermann TG, O’Neill K, Plas DR, Cahir-McFarland E. IKK beta and NF-kappa B transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1. Cancer Res. 2011;71:7291–300.

33. Lo AK, Lung RW, Dawson CW, Young LS, Ko CW, Yeung WY, et al. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr Virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma. J Pathol. 2018;246:180–90.

34. Wang XM, Proud CG. mTORC2 is a tyrosine kinase. Cell Res. 2016;26:1–2.

35. Horikawa T, Yoshizaki T, Kondo S, Furukawa M, Kaizaki Y, Pagano J. Epstein-Barr Virus latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma. J Pathol. 2018;246:180–90.

36. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–76.

37. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.

38. Wang XM, Proud CG. mTORC2 is a tyrosine kinase. Cell Res. 2016;26:1–2.

39. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med. 1995;333:693–8.